Regeneron Ireland Designated

Company snapshot

Regeneron Ireland Designated is a pharma organization headquartered in LA MESA, CA, IE. It trades on NYSE under ticker RGBP. Primary therapeutic focus areas include Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, Congenital Heart Disease, Congenital Heart Disease, SRV Dependent, Genitourinary Syndrome of Menopause. NovaPharmaNews links 10 clinical program(s), 51 drug profile(s), and 8292 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (5), approved (2), phase 2 (1).

• 52 approved product(s) across US/EU regulatory metadata.
• 10 active pipeline program(s) linked via ClinicalTrials.gov.
• 8292 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Regeneron Ireland Designated. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Regeneron Ireland Designated.

1. Jun 8, 2026 Clinical update

   Autologous (self) mononuclear cells derived from umbilical cord blood — Phase 2

2. Jun 8, 2026 Clinical update

   Regen Matrix-PRP-XLHA — Unknown

3. Jun 8, 2026 Clinical update

   hyaluronic Acid + platelet-rich plasma — Approved

4. Jun 8, 2026 Clinical update

   Cellular Matrix / A-CP-HA Kit — Approved

5. Jun 5, 2026 Clinical update

   Placebo — Unknown

View all clinical trial activity →

• What is Regeneron Ireland Designated?

  Regeneron Ireland Designated is a pharma organization headquartered in LA MESA, CA, IE. It trades on NYSE under ticker RGBP. Primary therapeutic focus areas include Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, Congenital Heart Disease, Congenital Heart Disease, SRV Depen

• Is Regeneron Ireland Designated publicly traded?

  Yes. Regeneron Ireland Designated is listed with ticker RGBP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Regeneron Ireland Designated develop or market?

  We link 62 drug profile(s) where Regeneron Ireland Designated is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/regen-biopharma-inc#company-drugs.

• What are the latest developments for Regeneron Ireland Designated?

  In the last 12 months our linked public records show 10 trial program update(s) and 152 US patent grant(s) tied to this profile.

• What therapeutic areas does Regeneron Ireland Designated focus on?

  Regeneron Ireland Designated focuses on Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, Congenital Heart Disease based on our analysis of their pipeline programs and drug development activities.